Indo US Bio-Tech Ltd

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Indo US Bio-Tech Ltd, a key player in the Other Agricultural Products sector, has recently experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside comparisons with industry peers and historical benchmarks. Investors are now reassessing the stock’s price attractiveness in light of these developments.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd has reported a significant downturn in its latest quarterly financial performance, marking a shift from a previously flat to a negative financial trend. The company’s December 2025 quarter results reveal contraction across key metrics including revenue, profitability, and earnings per share, signalling challenges ahead for this player in the Other Agricultural Products sector.

Indo US Bio-Tech Ltd’s stock declined sharply to a new 52-week low of Rs.109.7 today, marking a significant drop amid a challenging market environment and subdued financial performance. The stock’s fall contrasts with the broader market’s mixed movements, highlighting company-specific pressures.

Indo US Bio-Tech Ltd, a player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 19 Jan 2026. This shift reflects deteriorating technical indicators, flat recent financial performance, and a challenging near-term outlook despite some strong long-term fundamentals. The company’s Mojo Score has declined to 47.0, signalling caution for investors amid a 3.8% drop in share price on the downgrade day.

Indo US Bio-Tech Ltd, a player in the Other Agricultural Products sector, touched a fresh 52-week low of Rs.110.15 today, marking a significant decline amid broader market weakness and sector underperformance. The stock’s fall reflects ongoing pressures despite some underlying financial strengths.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 January 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Indo US Bio-Tech Ltd has seen its investment rating upgraded from Sell to Hold as of 29 Dec 2025, reflecting a nuanced improvement in technical indicators, valuation metrics, and financial trends despite recent flat quarterly performance. This shift highlights a cautious optimism among analysts amid ongoing market challenges and the company’s attractive long-term fundamentals.

Indo US Bio-Tech, a player in the Other Agricultural Products sector, is currently navigating a complex market environment marked by subdued financial results, shifting technical indicators, and valuation contrasts. Recent assessment changes reflect a nuanced view of the company’s prospects amid broader market dynamics.

Indo US Bio-Tech, a microcap player in the Other Agricultural Products sector, has experienced a revision in its market evaluation metrics, reflecting nuanced shifts across quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of mixed financial performance and subdued stock returns over the past year.

Indo US Bio-Tech Ltd witnessed a remarkable trading session on 26 Nov 2025, hitting its upper circuit limit with a near 20% gain. The stock's surge was driven by intense buying interest, resulting in a regulatory freeze on further transactions and highlighting significant unfilled demand in the market.

Indo US Bio-Tech Ltd witnessed extraordinary buying momentum on 26 Nov 2025, registering a remarkable 19.98% gain in a single trading session. The stock's price action was characterised by an upper circuit scenario with exclusively buy orders in the queue, signalling intense demand and a potential multi-day circuit continuation.

Indo US Bio-Tech has reached a new 52-week low of Rs.112.6, marking a significant decline in its stock price amid broader market gains and sectoral advances. The stock's recent performance contrasts sharply with the positive momentum observed in the agricultural sector and the wider market indices.